Freedom of Information Request: 0559 2019/20

Please can I request any information that is available for the below questions:

Does a specific venous thromboembolism protocol exist for your Trust

Yes

If so:

–          What date was this protocol put into place

           Last Policy reviewed and implemented November 2019

–          When is it due for review

     Next review is November 2022

Is there a preferred Direct Oral Anticoagulant (DOAC) or are all utilised within the trust for VTE

All direct oral anticoagulants for VTE are prescribed and utilised within the Trust. It is the clinician’s decision based on clinical indication, patient choice and the SMPc for the specific drug. However, APCC for BSOL CCG guidelines states Apixaban or Rivaroxaban as first line choice for VTE

How many patients have been treated for VTE with a DOAC in the last 12 months

We do not hold this information; our systems cannot differentiate between DOAC issued for VTE and for other indications.

What volume of each DOAC was used to Treat in this same time period

We do not hold this information; our systems cannot differentiate between DOAC issued for VTE and for other indications.